Israeli Health-Tech Startup Lands $1.6M Grant for Innovative At-Home Fertility Device

Key Takeaways

IMMA Health secures $1.6 million from the Israel Innovation Authority and earns the European Innovation Council’s Seal of Excellence.
The company is developing the first self-operated transvaginal ultrasound, enhancing accessibility to reproductive healthcare.
IMMA aims to transform fertility treatments and broader women’s health applications, while preparing for international market entry.

Groundbreaking Reproductive Health Technology

IMMA Health, an Israeli health-tech firm, recently received a $1.6 million grant from the Israel Innovation Authority and has been awarded the prestigious Seal of Excellence by the European Innovation Council (EIC). The company is at the forefront of developing the world’s first self-operated transvaginal ultrasound, which integrates robotics and artificial intelligence. This innovative platform allows women to independently conduct 3D pelvic ultrasound scans in the comfort of their homes. This technology aims to democratize access to essential reproductive healthcare and offer physicians automated, standardized reports, enhancing clinical decision-making.

The company’s device seeks to address critical issues in women’s healthcare, particularly the limited access to reproductive and fertility services. It is initially designed to improve fertility monitoring and potentially increase IVF success rates, impacting millions of women globally who seek fertility support. Beatrice Chemla, CEO and co-founder of IMMA Health, emphasized that the dual recognition underscores the company’s mission to empower women with control over their bodies while providing valuable insights to healthcare professionals.

The EIC’s Seal of Excellence is granted to only a select few deep-tech firms that showcase exceptional potential for both European and global impact. Experts commended IMMA’s innovation for its “game-changing” nature in IVF treatments and as a significant advancement in ultrasound diagnostics. They highlighted the project’s ability to address urgent global trends, such as declining fertility rates and the increasing demand for remote healthcare solutions, potentially transforming healthcare delivery for clinics and patients alike.

While focusing on fertility initially, IMMA’s technology also holds promise for broader applications in women’s health. The firm indicates its platform could aid in the early detection of conditions like endometriosis, Polycystic Ovary Syndrome (PCOS), and certain cancers through less invasive methods. Chemla noted that the technology could make fertility treatments more affordable, accessible, and private compared to traditional settings.

Currently, IMMA Health is finalizing its seed funding round, with plans to expedite development, conduct clinical trials, and pursue regulatory approvals in the U.S. and Europe. The company is strategically positioned to revolutionize women’s health technology while working towards FDA approval and international regulatory compliance. With these significant advancements and recognitions, IMMA Health aims to redefine the landscape of reproductive healthcare on a global scale.

The content above is a summary. For more details, see the source article.